Optimization of early markers for the diagnosis of preeclampsia on the background of metabolic syndrome

Keywords: preeclampsia, metabolic syndrome, vitamin D, inhibin A, insulin-like growth factor.


Annotation. Preeclampsia remains a mysterious puzzle for clinicians and researchers who have been uncovering it for decades. The search for new modern diagnostic markers for the possibility of early prevention of this complication will facilitate the course of pregnancy and childbirth. Preeclampsia can affect 2-8% of all pregnancies. The study of angiogenic biomarkers to stratify the risk of disease is the aim of our study. Patients are divided into groups due to the severity of preeclampsia. Group I included 26 pregnant women with moderate preeclampsia, diastolic blood pressure was up to 90 m Hg, to group II – 20 pregnant women with moderate preeclampsia, the level of diastolic pressure was up to 99 m Hg. The third group included pregnant women in whom the physiological course of pregnancy without complications and concomitant extragenital pathology. Inhibin A levels were determined using a Beckmann Coulter analyzer and test system (Germany); ELISA Testkit, Access-Inhibin A Kit by Beckmann Coulter, the concentration of vitamin D in the serum of patients was determined using an analyzer and test system Immulite (Siemens AG, Germany). Statistical analysis of the obtained results was performed minus the mean value (M) and the standard error of the mean value (m). Qualitative indicators are presented in the form of %. Comparison of quantitative indicators with normal distribution was performed by Student’s t test (p<0.05), and with abnormal distribution in unrelated samples – using Mann-Whitney test (U test), comparison of relative values – using χ2 (chi) -square). A significant relationship (p=0.041) was found between inhibin A levels and the occurrence of preeclampsia. Vitamin D deficiency (24.5±1.01 ng/ml) was also found in women in the study groups. The level of placental growth factor in all women in the first trimester of pregnancy was 45.93±11.74 pg/ml, which corresponds to normal values. The mean level of insulin-like growth factor was reduced (120.87±4.12 ng/ml) compared with the control group (224.1±6.24 ng/ml). Thus, increased inhibin A, decreased IGF, and vitamin D deficiency may be a marker for a patient at risk for preeclampsia.


[1] Bokslag, A., van Weissenbruch, M., Mol, B. W., & de Groot, C. J. (2016). Preeclampsia; short and long-term consequences for mother and neonate. Early human development, 102, 47-50. https://doi.org/10.1016/j.earlhumdev.2016.09.007

[2] Broumand, F., Lak, S. S., Nemati, F., & Mazidi, A. (2018). A study of the diagnostic value of Inhibin A tests for occurrence of preeclampsia in pregnant women. Electronic physician, 10(1), 6186-6192. https://doi.org/10.19082/6186)

[3] Chau, K., Hennessy, A., & Makris, A. (2017). Placental growth factor and preeclampsia. J Hum Hypertens, 31(12), 782-786. https://doi.org/10.1038/jhh.2017.61

[4] Filipek, A., & Jurewicz, E. (2018). Preeklampsja – choroba kobiet w ciąży [Preeclampsia - a disease of pregnant women]. Postepy biochemii, 64(4), 232-229. https://doi.org/10.18388/pb.2018_146

[5] Maeda, K. (2013). Preeclampsia is caused by continuous sympathetic center excitation due to an enlarged pregnant uterus. J Perinat Med., 42(2), 233-237. https://doi.org/10.1515/jpm-2013-0096

[6] Neuman, R. I., Alblas van der Meer, M. M., Nieboer, D., Saleh, L., Verdonk, K., Kalra, B., … & Danser, A. (2020). PAPP-A2 and inhibin A as novel predictors for pregnancy complications in women with suspected or confirmed preeclampsia. Journal of the American Heart Association, 9(19), e018219. https://doi.org/10.1161/JAHA.120.018219

[7] Phupong, V., Paiwattananupant, K., & Honsawek, S. (2009). Inhibin A levels and severity of preeclampsia. Archives of gynecology and obstetrics, 280(2), 183-186. https://doi.org/10.1007/s00404-008-0886-y

[8] Pinheiro, C. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenat Diagn., 34(11), 1084-1092. https://doi.org/10.1002/pd.4432

[9] Rana, S., Lemoine, E., Granger, J. P., & Karumanchi, S. A. (2019). Preeclampsia: pathophysiology, challenges, and perspectives. Circulation research, 124(7), 1094-1112. https://doi.org/10.1161/CIRCRESAHA.118.313276

[10] Shen, Z., Cai, L. Y., Suprapto, I. S., Shenoy, P., & Zhou, X. (2011). Placental and maternal serum inhibin A in patients with preeclampsia and small-for-gestational-age. The journal of obstetrics and gynaecology research, 37(10), 1290-1296. https://doi.org/10.1111/j.1447-0756.2010.01513.x)
How to Cite
Franchuk, U. Y., Khmil, S. V., Malanchuk, L. M., & Malanchyn, I. M. (2022). Optimization of early markers for the diagnosis of preeclampsia on the background of metabolic syndrome. Reports of Vinnytsia National Medical University, 26(1), 49-52. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2022-26(1)-09